Clinical effect of chemotherapy combined with hyperthermia for treatment of patients with advanced colorectal cancer
10.16781/j.0258-879x.2016.02.0173
- Author:
Ming WU
1
Author Information
1. Department of General Surgery, Tinglin Hospital of Shanghai
- Publication Type:Journal Article
- Keywords:
Adverse reaction;
Colorectal neoplasms;
Drug therapy;
Hyperthermia;
Survival rate
- From:
Academic Journal of Second Military Medical University
2016;37(2):173-176
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of CapeOx(XELOX) chemotherapy combined with hyperthermia in treating patients with advanced colorectal cancer. Methods A total of 80 patients with advanced colorectal cancer were evenly randomized into two groups: the combined group underwent CapeOx (XELOX) chemotherapy and hyperthermia(on the 1st, 5th. and 10th days of chemotherapy), while the control group only received chemotherapy. The treatment efficacies (evaluated by Response Evaluation Criteria in Solid Tumors [RECIST]), scrum levels of carcinoembryonic antigen (CEA) and adverse reactions were compared between the two groups. The survival rates of two groups were recorded and analyzed. Results RECIST results showed that the rate of complete remission plus partial remission in combined group was 67. 5%(27/40), which was significantly higher than that in the control group (35. 0%[l4/40]. P<0. 05). The serum levels of CEA were decreased in both group after treatment, with that in the combined group being significantly lower than that in the control group([101. 3 ± 58.1] vs [213. 6±100. 3] ng/mL, P<0. 05). The adverse reaction (leukocyte decrease, gastrointestinal reaction, and peripheral nerve reaction) rate of the combined group was significantly lower than that in the control group(P<0. 05). The 2-month survival rates were 100. 0% in both groups (P>0. 05); while the 2-ycar survival rate of the combined group was significantly higher than that in the control group (37. 5% [15/40] vs 12. 5% [5/40], P
